A NEW treatment for chronic
obstructive pulmonary disease
(COPD), will be available on the PBS
from 01 December 2011, Onbrez
Breezhaler (indacaterol).
The new listing will expand the
range of therapy options for Aussie
patients, with the once-daily longacting
â2-agonist (LABA) being the
first approved LABA to combine
clinically relevant 24-hour
bronchodilation with rapid onset of
action within five minutes of
administration of the first dose.
Onbrez is administered using the
Breezhaler device, which provides
patients with dosing feedback.The above article was sent to subscribers in Pharmacy Daily's issue from 29 Nov 11 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Nov 11
PEAK pharmacy bodies are calling on the Australian Government to extend the new Commonwealth Prac Payment to pharmacy students, citing the challenges of “placement poverty” in unpaid practical placements.
AFT Pharmaceuticals is set to develop a topical treatment for keloid and hypertrophic scarring in partnership with NZ’s Massey Ventures, the commercialisation arm of Massey University, and the Gillies McIndoe Research Institute.
THE Pharmaceutical Society of Australia (PSA) awarded Brooke Shelly the prestigious 2024 PSA MIMS Credentialed Pharmacist of the Year award last Fri at the Credentialed Pharmacist Conference (CPC24) (PD breaking news).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.